Genfit (GNFT) Stock Forecast, Price Target & Predictions
GNFT Stock Forecast
Genfit stock forecast is as follows: an average price target of $13.00 (represents a 248.53% upside from GNFT’s last price of $3.73) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
GNFT Price Target
The average price target for Genfit (GNFT) is $13.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $13.00. This represents a potential 248.53% upside from GNFT's last price of $3.73.
GNFT Analyst Ratings
According to 1 Wall Street analysts, Genfit's rating consensus is 'Buy'. The analyst rating breakdown for GNFT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Genfit Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 23, 2024 | Ed Arce | H.C. Wainwright | $13.00 | $5.03 | 158.45% | 248.53% |
The latest Genfit stock forecast, released on Sep 23, 2024 by Ed Arce from H.C. Wainwright, set a price target of $13.00, which represents a 158.45% increase from the stock price at the time of the forecast ($5.03), and a 248.53% increase from GNFT last price ($3.73).
Genfit Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $13.00 |
| Last Closing Price | $3.73 | $3.73 | $3.73 |
| Upside/Downside | -100.00% | -100.00% | 248.53% |
In the current month, the average price target of Genfit stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Genfit's last price of $3.73. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 23, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Genfit's last stock rating was published by H.C. Wainwright on Sep 23, 2024. The company gave GNFT a "Buy" rating, the same as its previous rate.
Genfit Financial Forecast
Genfit Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Avg Forecast | $58.70M | $59.89M | $48.05M | $76.76M |
| High Forecast | $58.70M | $59.89M | $48.05M | $76.76M |
| Low Forecast | $58.70M | $59.89M | $48.05M | $76.76M |
| # Analysts | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - |
Genfit's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. GNFT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Genfit EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - |
| Avg Forecast | $-39.24M | $-40.04M | $-32.12M | $-51.31M |
| High Forecast | $-39.24M | $-40.04M | $-32.12M | $-51.31M |
| Low Forecast | $-39.24M | $-40.04M | $-32.12M | $-51.31M |
| Surprise % | - | - | - | - |
undefined analysts predict GNFT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Genfit's previous annual EBITDA (undefined) of $NaN.
Genfit Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - |
| Avg Forecast | - | $84.85M | $18.96M | $46.79M |
| High Forecast | - | $84.85M | $18.96M | $46.79M |
| Low Forecast | - | $84.85M | $18.96M | $46.79M |
| Surprise % | - | - | - | - |
Genfit's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GNFT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Genfit SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - |
| Avg Forecast | $418.91M | $427.40M | $342.91M | $547.81M |
| High Forecast | $418.91M | $427.40M | $342.91M | $547.81M |
| Low Forecast | $418.91M | $427.40M | $342.91M | $547.81M |
| Surprise % | - | - | - | - |
Genfit's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to GNFT last annual SG&A of $NaN (undefined).
Genfit EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - |
| Avg Forecast | - | $1.41 | $0.31 | $0.78 |
| High Forecast | - | $1.41 | $0.31 | $0.78 |
| Low Forecast | - | $1.41 | $0.31 | $0.78 |
| Surprise % | - | - | - | - |
According to undefined Wall Street analysts, Genfit's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GNFT previous annual EPS of $NaN (undefined).
Genfit Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KROS | Keros Therapeutics | $11.37 | $101.00 | 788.30% | Buy |
| ANTX | AN2 Therapeutics | $1.18 | $8.75 | 641.53% | Buy |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| AVTE | Aerovate Therapeutics | $2.58 | $13.00 | 403.88% | Hold |
| ACRV | Acrivon Therapeutics | $5.55 | $22.50 | 305.41% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.54 | $6.00 | 289.61% | Buy |
| GNFT | Genfit | $3.73 | $13.00 | 248.53% | Buy |
| ADAG | Adagene | $1.85 | $5.00 | 170.27% | Buy |
| FENC | Fennec Pharmaceuticals | $6.47 | $15.75 | 143.43% | Buy |
| JANX | Janux Therapeutics | $42.51 | $70.25 | 65.26% | Buy |
| EWTX | Edgewise Therapeutics | $28.42 | $46.25 | 62.74% | Buy |
| RZLT | Rezolute | $5.06 | $6.67 | 31.82% | Buy |
| HRMY | Harmony Biosciences | $38.82 | $45.33 | 16.77% | Buy |